 Home > Medical News > Latest Medical News > Janssen's new RSV fusion protein inhibitor plans to be included in breakthrough treatment varieties

Janssen's new RSV fusion protein inhibitor plans to be included in breakthrough treatment varieties

 Last Update: 2021-04-27
 Source: Internet
 Author: User

Tags

cell activity

c60 human studies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to the latest announcement on the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, the JNJ-53718678 oral suspension developed by Johnson & Johnson's Janssen company is intended to be included in the breakthrough treatment category.

Screenshot source: CDE official website

RSV is the main cause of pneumonia and bronchiolitis in young children and the elderly.

As a new oral inhibitor of RSV fusion protein, JNJ-53718678 can specifically target and bind to the fusion protein on the surface of the virus, inhibit RSV fusion protein-mediated fusion with the host cell membrane, and prevent the virus from entering.

According to the information on the ClinicalTrials.

At present, Janssen is carrying out a number of clinical trials on JNJ-53718678: one of them is a randomized, double-blind, placebo-controlled phase 2 clinical trial, which aims to evaluate the hematopoiesis of JNJ-53718678 in adults and adolescents infected with RSV in the upper respiratory tract.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.